Edgewise Pharma (EWTX): Price-to-Revenue Ratio

Brandmark of Edgewise Therapeutics Inc (EWTX)

The price-to-sales ratio provided by the GURU.Markets service demonstrates the market valuation of Edgewise Therapeutics (EWTX), where defines the current value of the metric. Edgewise Therapeutics (EWTX) creates breakthrough molecules for muscular dystrophy therapy by implementing a precision approach. The business possesses high macro-resilience, as medical progress is independent of economic cycles, and a stable staff of scientists eliminates any shortage of key competencies.

EWTX Edgewise Therapeutics P/S Multiple (07/04/2022 - 11/14/2026)

Analytical breakdowns for Edgewise Pharma (EWTX)

- current quotes and average value forecast:
Market Price edgewisetx.com|EWTX - Price Target Chart
- stock exchange capitalization data:
Market Value Edgewise Pharma|EWTX - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Edgewise Therapeutics|EWTX - Book Capitalization|Market Value to Equity Ratio edgewisetx.com|EWTX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Edgewise Therapeutics|EWTX - Long-Term Debt to Capital|Current Liabilities to Capital Edgewise Corp|EWTX - Company Aggregate Debts|Debt to Book Value Ratio Edgewise Pharma|EWTX - Company Long-Term Debts|Short-Term Indebtedness Edgewise Therapeutics|Immediate Liquidity edgewisetx.com
- earnings and multiples data:
EWTX - Net Income|Future Profit Edgewise Therapeutics|EWTX - P/E Multiple|Market Cap to Projected Earnings Edgewise Therapeutics Inc|EWTX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Edgewise Pharma|EWTX - Operating profit EBITDA|Net earnings per one share for the last twelve months Edgewise Therapeutics|EWTX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months edgewisetx.com|EWTX - Net earnings per share growth this year|Projected earnings per share increase next year Edgewise Therapeutics
- issuer revenue and sales details:
EWTX - Revenue and Sales Volume|Company Future Revenue edgewisetx.com|EWTX - P/S Multiple|Market Cap to Future Revenue Ratio Edgewise Pharma
General company analysis:edgewisetx.com (EWTX)
Mass-produced product of Edgewise Therapeutics, Inc.

The P/S ratio reflects the market value of a business relative to its operating revenues, allowing for an assessment of the premium paid for each unit of revenue. For the biotech sector, the price-to-sales ratio for Edgewise Therapeutics (EWTX), with its current value of , serves as an indicator of market expectations regarding the success of its small molecule platform in treating myopathies, helping investors distinguish speculative peaks from fundamental value.

Competing companies

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple rapportrx.com RAPP|Market Cap to Revenue ALMS|Price to Sales Zevra Therapeutics Inc ZVRA|P/S Multiple CTNM|LRMR - Price to Sales|P/S Multiple CAPR (Capricor Therapeutics, Inc.)|TRDA: Market Cap to Revenue Ratio|Channel Therapeutics Corp - P/S Multiple|Price-to-Revenue Multiple MediciNova, Inc. (MNOV)|SER: P/S Multiple|Price to Sales BioXcel Therapeutics Corp (BTAI)|Market Cap to Revenue PMN|Market Cap to Revenue Apimeds (APUS)|P/S Multiple AEON|Price-to-Revenue Coefficient nlspharma.com|Price-to-Revenue Ratio Bionomics BNOX|Price-to-Revenue Coefficient fsdpharma.com (HUGE)|Reata Pharmaceuticals - P/S Multiple